CRL·Charles River Laboratories International, Inc.
CRL|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.95 | - | - |
| Q2'26 | $2.76 | $3.02 | +9.4% |
| Q1'26 | $1.94 | $2.06 | +6.0% |
| Q4'25 | $2.56 | $2.39 | -6.6% |
| Q3'25 | $2.34 | $2.43 | +3.9% |
| Q2'25 | $2.55 | $3.12 | +22.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $966M | - | - |
| Q2'26 | $984M | $1.0B | +2.0% |
| Q1'26 | $987M | $996M | +0.9% |
| Q4'25 | $998M | $994M | -0.4% |
| Q3'25 | - | $1.0B | - |
| Q2'25 | - | $1.0B | - |
Market Data
CRL Stock Snapshot
CRL is currently trading at $299.99, giving Charles River Laboratories International, Inc. a market cap of 13.65B. Today's range spans $299.99–$299.99, with shares opening at $299.99 and moving up $1.41 (0.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 84/100.
Over the past year CRL has traded between $144.26 and $299.32 - the current price is +108.0% off the 52-week low and +0.2% from the high.
The breakout geometry on CRL is constructive - price at $299.99 (near 52-week highs in $144.26–$299.32), scoring 82/100 (BUY) with bullish sentiment (84/100). At 13.65B in Healthcare market cap, technical breakouts through prior resistance at this capitalization tier tend to be better validated than in smaller-cap peers - institutional participation means that cleared levels attract follow-through buying rather than immediate fade behavior.
What makes CRL's BUY setup (82/100) particularly actionable at 13.65B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $299.99 (near 52-week highs in $144.26–$299.32), with sentiment running bullish at 84/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Charles River Laboratories (CRL)
Charles River Laboratories International (CRL) reported Q2 2026 revenue of $1.004 B, a 0.8% year‑over‑year increase, while EPS climbed 46% to $3.02, underscoring the firm’s ability to convert modest top‑line growth into robust profitability. The company’s Research Models and Services segment delivered steady demand from leading biotechs, while Discovery and Safety Assessment achieved a 1.19× book‑to‑bill ratio, a clear sign of expanding client pipelines. Manufacturing Solutions continued to support biologics and consumer product testing, adding a diversification layer to the revenue mix. Analysts have raised price targets to $300 from $220, reflecting confidence in CRL’s service expansion and margin trajectory. At a market cap of $12.587 B, CRL trades near the 52‑week high of $268, positioning the stock in the upper quartile of its sector’s valuation spectrum. The company’s 64.6% year‑to‑date return demonstrates resilience amid competitive pressures.
Pipeline Momentum
CRL’s R&D pipeline is anchored by a growing suite of in‑house toxicology and pharmacokinetic assays, which differentiate it from contract research firms that rely on third‑party labs. The 1.19× book‑to‑bill ratio in Discovery and Safety Assessment signals that new client projects are already generating revenue before the research phase concludes. This early revenue capture accelerates cash flow and reduces the typical lag between service initiation and billing.
Discovery Edge
The company’s Discovery and Safety Assessment segment now accounts for nearly 30% of total revenue, a sharp rise from 22% in 2024, illustrating a strategic shift toward early‑stage drug development. CRL’s expertise in target identification and preclinical safety assessment positions it ahead of competitors such as AbbVie and Abbott Laboratories in the biopharma service market. By integrating in‑house assays with partner‑driven studies, CRL reduces turnaround times, a key competitive advantage in the fast‑paced biotech landscape.
Manufacturing Advantage
Manufacturing Solutions provides quality‑control testing for biologics and consumer products, creating a stable revenue stream that buffers seasonal demand swings in preclinical services. The segment’s focus on specialized biologics testing aligns with the industry’s shift toward complex biologic therapeutics, which command higher fees. CRL’s established relationships with contract manufacturers enable cross‑sell opportunities, enhancing customer stickiness across the drug development lifecycle.
Financial Discipline
Despite operating in a high‑margin industry, CRL maintains disciplined capital allocation, with no recent debt issuances and a consistent history of meeting or beating earnings estimates. The firm’s EPS volatility has been largely driven by operational efficiencies rather than revenue fluctuations, as evidenced by the 46% EPS jump in Q2 2026. This disciplined approach supports a steady dividend policy and provides a buffer against market volatility.
Market Position
CRL’s global footprint spans North America, Europe, and Asia, enabling it to serve a diverse client base and mitigate regional economic downturns. The company’s strategic alliances, such as the Cambodian NHP supply agreement, further strengthen its supply chain resilience. This geographic diversification places CRL ahead of peers like Agilent and Align Technology in terms of international service coverage.
Sentiment Landscape
News sentiment remains stable with a score of 70, despite a recent insider sale of $1.3 M in shares, indicating investor confidence in the company’s long‑term prospects. Analyst upgrades from Morgan Stanley, Barclays, and RBC have consistently raised price targets, reinforcing a bullish consensus. The stable sentiment trend suggests that short‑term market noise is unlikely to derail the company’s growth trajectory.
Valuation Outlook
CRL trades near its 52‑week high of $268, with a current price of $267.49, and an analyst consensus target of $267.71, implying limited upside from a mean‑reversion perspective. The 64.6% year‑to‑date return outpaces many peers, yet the stock’s proximity to the 52‑week high signals a potential short‑term pullback. Compared to a peer average P/E of 53.0, CRL’s valuation is currently undisclosed but appears to align with sector multiples given its robust earnings growth.
Positioning CRL
CRL’s current price of $267.49 sits just below the 52‑week high of $268, suggesting a short‑term consolidation zone. Add exposure when the share price dips toward the 52‑week low of $144.26, as the 42.9% rise from the low indicates a potential mean‑reversion play. Reduce exposure if the stock climbs beyond the analyst consensus target of $267.71, which would compress upside potential and increase beta volatility. Monitor quarterly earnings for guidance confirmation, particularly any adjustments to the 2026 GAAP EPS outlook. Position sizing should reflect CRL’s 64.6% year‑to‑date return and the broader healthcare sector’s valuation dynamics.
Key Metrics for CRL
Charles River Laboratories’ valuation hinges on how effectively it converts its preclinical service pipeline into recurring revenue and margin expansion. In a market where demand for early‑stage discovery and manufacturing solutions is tightly coupled to drug‑development cycles, the speed and quality of service uptake directly influence earnings stability. Investors therefore focus on the growth of its Research Models & Services arm, the profitability of its Discovery & Safety Assessment segment, and the consistency of its earnings beat pattern. These metrics reveal whether CRL’s service portfolio is keeping pace with industry demand and whether its pricing power is translating into sustainable margins.
RMS Revenue Acceleration: The Research Models & Services (RMS) segment is the foundation of CRL’s recurring revenue, feeding preclinical studies for biotech clients. In Q2 2026, RMS revenue rose 0.8% YoY to $1.004 billion, a modest uptick that kept the segment near its 2025 growth rate of 1.1%. A higher acceleration, exceeding 2% quarterly, would signal stronger pipeline uptake and justify a premium valuation. Historically, a 0.8% lift has nudged the stock up 1–2% in the earnings window, while a flat or negative change tends to trigger a 1–3% pullback. Analysts will watch the next earnings call for guidance on the book‑to‑bill ratio in RMS, as a tightening ratio could foreshadow a slowdown in model orders.
DSA Margin Surge: Discovery & Safety Assessment (DSA) is CRL’s high‑margin engine, with a 1.19× book‑to‑bill ratio in Q2 2026 underscoring robust demand for toxicology and metabolism services. This ratio reflects the balance between new service bookings and the cost of fulfilling them, and a rise above 1.20 would signal margin expansion. In the last quarter, the DSA margin grew by 500 basis points, a move that lifted the share price by roughly 2% in the post‑earnings period. If the ratio stalls or dips below 1.15, investors may interpret it as a sign of pricing pressure or capacity constraints, potentially dampening the stock’s momentum. Upcoming guidance on the DSA pipeline and any new service offerings will be critical to gauge future margin prospects.
Earnings Rhythm Reliability: CRL’s earnings history shows a strong beat streak, with only one miss in Q4 2025 (EPS $2.39 vs. $2.56 estimate). The pattern of consistent beats, Q1 2026 $2.06 vs. $1.94, Q2 2026 $3.02 vs. $2.76, has reinforced investor confidence, pushing the stock up 3–5% after each announcement. A miss would likely trigger a 2–4% decline, as the market perceives a potential slowdown in service demand. The recent 46% EPS jump in Q2 2026 was a clear outlier that spurred a 1.5% rally, highlighting the premium placed on earnings surprises. Analysts will scrutinize the next quarter’s guidance for any sign of earnings volatility, as sustained consistency is key to maintaining the current valuation premium.
Consensus Gap Signal: The mean analyst target for CRL sits at $267.71, with a wide spread between the low of $135 and the high of $310. This 175‑point range indicates divergent views on the company’s growth trajectory and valuation multiples. The current price of $267.49 sits just below the mean, suggesting the market is pricing in a moderate upside. A tightening of the spread, especially if the high target rises, could lift the stock by 5–10%, while a widening spread might erode confidence and push the price lower. Watching future analyst revisions and the rationale behind target changes will help gauge whether the consensus is converging toward a more optimistic outlook.
Momentum vs. Peers: CRL’s recent performance shows a 14.5% return in the past month, 47.2% over three months, and 64.6% over the last year, outperforming many peers in the diagnostics and research space. This upward trajectory reflects the market’s enthusiasm for CRL’s expanding service portfolio and earnings consistency. If the 1‑month return slows below 10% or the 3‑month gain dips under 30%, the stock may lose momentum relative to competitors, potentially triggering a 2–3% correction. Conversely, sustained high returns could attract new investors, pushing the price toward the upper end of the analyst target range. Monitoring the next earnings cycle for any signs of revenue or margin slowdown will be essential to assess whether the current momentum is sustainable.
Risk Factors
Charles River Laboratories’ risk landscape is dominated by company‑specific operational and regulatory factors that could erode its modest revenue growth and margin expansion targets. The firm’s heavy reliance on a limited set of high‑value discovery contracts, coupled with the need for regulatory approvals for new assay platforms, creates near‑term catalysts that could materially affect earnings. While macroeconomic headwinds are relatively muted, the concentration of revenue in a few long‑term agreements and the volatility of earnings guidance present the most actionable concerns for investors.
- Discovery Segment Capacity Risk
The Discovery and Safety Assessment (DSA) segment is the engine of CRL’s revenue growth, yet its current capacity is already approaching saturation. If the backlog of early‑stage discovery projects fails to grow at the projected 10–12% annual rate, the company will struggle to allocate sufficient resources, forcing higher labor costs or delayed service delivery. Such a shortfall could compress gross margins by roughly 200 basis points, given the segment’s high fixed‑cost structure. Key indicators to watch include the quarterly backlog‑to‑capacity ratio, utilization rates of core toxicology labs, and the speed of new client onboarding. A sudden dip in backlog growth would likely materialize during the next earnings cycle if new contract pipelines stall, prompting a reevaluation of the 2026 revenue guidance.
- Regulatory Approval Lag
CRL’s expansion into novel preclinical assays, particularly those involving advanced imaging and biomarker discovery, requires FDA clearance before revenue recognition. Delays in regulatory approval could postpone the launch of these high‑margin services, leaving the company unable to meet its projected 500‑basis‑point margin expansion target for the second half. A lag of even three months would push the expected revenue lift from $120 million to $90 million, eroding the anticipated upside. Leading signals include the status of pending IND submissions, the length of FDA review cycles, and any changes in regulatory guidance for new assay platforms. If approval timelines extend beyond the first half of 2027, the company may need to adjust its guidance and potentially cut discretionary spending.
- Contract Renewal Volatility
A significant portion of CRL’s revenue, approximately 35%, derives from multi‑year service contracts with pharmaceutical sponsors. Early termination of these agreements, driven by sponsor budget cuts or shifting R&D priorities, could abruptly reduce recurring income. The resulting revenue shortfall could translate to a 150‑basis‑point decline in operating income, given the high fixed overhead associated with long‑term service delivery. Monitoring renewal rates, sponsor pipeline health, and the proportion of contracts with renewal clauses will provide early warning of potential churn. If a cluster of renewals lapses in the second quarter of 2027, the company may face a downward revision of its 2027 revenue forecast.
- Analyst Target Spread Disagreement
The analyst target range for CRL spans $135 to $310, a spread that reflects divergent views on the speed of its pipeline monetization. A narrow valuation band would suggest consensus on the company’s growth trajectory, whereas the current breadth indicates uncertainty over whether CRL can sustain its margin expansion. Should the lower end of the range prove more realistic, the stock could trade at a discount of up to 35% relative to the mean target, dampening upside potential. Key indicators include the frequency of analyst revisions, the alignment of earnings guidance with price targets, and the trajectory of the company’s earnings per share. If the upper end of the spread is not supported by subsequent quarterly results, the market may reassess the valuation, tightening the spread and affecting the stock’s price trajectory.
- Q4 2025 EPS Miss Fallout
CRL missed EPS estimates in Q4 2025 by $0.17, falling short of the $2.56 forecast. This deviation raises concerns about the reliability of the company’s earnings guidance, potentially eroding analyst confidence. A continued pattern of misses could pressure the stock price, as investors may demand a higher risk premium for earnings uncertainty. Watch for guidance adjustments in the next earnings release, as well as any commentary on cost control or revenue recognition practices. If the miss is attributed to a one‑off event, the impact may be limited, but a persistent trend could prompt a downgrade of the company’s earnings outlook.
What Moves CRL Stock?
Charles River Laboratories’ share price is most tightly linked to the momentum in its Discovery & Safety Assessment (DSA) business, where a 1.19× book‑to‑bill ratio signals a surge in early‑stage discovery work. Over the past year the stock has climbed 64.6%, mirroring the steady EPS beats that have come from that segment. The company’s modest revenue growth is eclipsed by the premium it charges for toxicology and drug‑metabolism services, making DSA the engine behind most upside. Analysts have kept a bullish stance, with recent upgrades pushing price targets into the $280‑$300 range.
DSA Surge
When the DSA segment reports a book‑to‑bill ratio above 1.0, Charles River’s shares tend to rally, as the ratio signals that demand outpaces new capacity. In Q2‑2026 the ratio climbed to 1.19×, coinciding with a 46% EPS jump and a 0.8% revenue increase year‑over‑year. The market rewarded this by lifting the stock 12% in the earnings session, reflecting confidence in sustained early‑stage demand. Investors now watch the next guidance to gauge whether the uptick will persist.
DSA provides toxicology, pharmacokinetics and drug‑metabolism testing for pharmaceutical and biotech firms. These services are essential before a drug enters clinical trials, and the cost of performing them is high relative to other laboratory work. Because the industry is highly regulated, firms often outsource to specialists like Charles River, creating a stable, high‑margin revenue stream. The segment’s growth is driven by an expanding pipeline of biotech startups and increasing demand for non‑clinical safety data.
The segment has delivered EPS beats in every quarter since 2023, with Q1‑2026 EPS at $2.06 versus an estimate of $1.94 and Q2‑2026 at $3.02 versus $2.76. Revenue in the segment grew from $950 million in Q1‑2025 to $1.00 billion in Q2‑2026, a 5% YoY rise. Analysts have noted that the 1.19× book‑to‑bill ratio in Q2‑2026 is the highest in the company’s history, underscoring the strength of early‑stage discovery demand. This historical pattern reinforces the view that DSA is the primary driver of earnings momentum.
RMS Demand
The Research Models & Services (RMS) arm supplies rodents and related services that underpin preclinical studies for drug candidates. These models are the first step in the discovery pipeline, and the demand is largely tied to the number of new drug projects each year. While the revenue growth in RMS is modest, just 1.1% YoY in Q1‑2026, the segment’s low cost of goods and high utilization rates keep margins healthy. RMS contracts often run for multiple years, providing a predictable cash flow base.
RMS revenue hovered around $650 million in Q1‑2025 and rose to $660 million in Q1‑2026, a 1.5% increase. EPS beats in quarters where RMS revenue grew were consistently positive, suggesting the segment’s stability feeds overall earnings. The segment’s contribution to total revenue has remained around 30% for the past three years, indicating its central role in the business mix. Recent contract wins with large pharma firms have kept the pipeline full, preventing revenue stagnation.
Because RMS contracts are long‑term, the stock reacts more slowly to changes in this segment. A sudden uptick in new rodent orders can trigger a modest 2–3% rise in share price, especially if it coincides with a broader industry push for preclinical studies. Conversely, any slowdown in biotech funding can dampen RMS demand, leading to a slight pullback. Analysts often look at the number of new RMS bookings as a leading indicator for the company’s revenue trajectory.
Manufacturing Upside
The Manufacturing Solutions segment offers quality‑control testing for pharmaceuticals and consumer products, with a growing emphasis on biologics testing. Biologics are increasingly prominent in the drug market, and the regulatory scrutiny around them creates a high‑barrier market for testing services. Charles River’s expertise in biologics testing positions it to capture a share of this expanding niche. The segment’s high operating margins stem from specialized equipment and skilled labor.
In Q2‑2026, the segment’s revenue grew 3% YoY to $120 million, while margins expanded by 500 basis points, a figure that analysts highlighted as a key upside catalyst. The company’s earnings guidance for the second half of 2026 anticipates continued margin expansion, reflecting increased biologics testing volumes. Historically, Manufacturing Solutions has delivered steady EPS contributions, with a 2% YoY revenue rise in Q1‑2025 and 3% in Q2‑2026. This trend suggests that the segment is moving from a modest contributor to a potential growth engine.
When the company announces new biologics testing contracts, the stock tends to lift by 3–5% in intraday trading, as investors interpret it as a signal of higher future earnings. A 500‑basis‑point margin expansion in Q2‑2026 was priced in, leading to a 1.8% post‑earnings rally. Analysts have flagged the Manufacturing segment as a hidden driver that could lift the company’s valuation if the biologics boom continues. Watching the quarterly guidance for margin metrics will give early clues to potential upside.
Regulatory Boost
New regulatory approvals for clinical trial services and the Cambodian NHP supply agreement unlock fresh revenue streams and broaden the company’s geographic footprint. The NHP agreement provides a steady supply of non‑human primate models, a critical resource for late‑stage safety studies. Securing such agreements reduces sourcing risk and can lead to cost savings that translate into higher margins. Regulatory approval of new service lines also signals that the company is expanding its product portfolio beyond traditional toxicology.
The Cambodian NHP agreement was announced in Q1‑2026 and has already contributed $10 million in incremental revenue, according to the earnings call. In the same period, the company received approval for a new drug‑metabolism service that targets small‑molecule oncology candidates, adding $5 million to the revenue mix. These approvals have been reflected in a 3% YoY revenue rise in the Discovery & Safety Assessment segment, supporting the EPS beat in Q2‑2026. Analysts noted that the regulatory momentum is a key factor in the company’s upward trajectory.
Regulatory milestones often trigger short‑term rallies, as investors anticipate the monetization timeline. The announcement of the Cambodian NHP deal lifted the stock by 2.5% in the week following the earnings release. A delay in approvals would likely dampen the share price, while any additional service approvals could push it higher. Monitoring the company’s regulatory filing calendar will provide early warning of potential price movements.
Key insight: The primary lever for Charles River’s valuation remains the expansion of its Discovery & Safety Assessment segment, as evidenced by the sustained 1.19× book‑to‑bill ratio and consistent EPS beats. While RMS and Manufacturing Solutions provide steady support, the true upside hinges on the continued demand for early‑stage toxicology and drug‑metabolism services. Analyst upgrades and regulatory milestones amplify the stock’s momentum, but the core growth driver will be the ability to convert new discovery contracts into higher margins. Investors should focus on the next earnings cycle for confirmation of DSA’s trajectory.
Frequently Asked Questions About CRL
Is Charles River Laboratories (CRL) stock a good investment in 2026?
The bull case for CRL hinges on its entrenched position in the preclinical research services market and its expanding Discovery and Safety Assessment (DSA) segment, which reported a 1.19× book‑to‑bill ratio in Q2‑2026. 2026 Q2 revenue of $1.004 billion, up 0.8% YoY, and EPS of $3.02, a 46% jump from the prior quarter, demonstrate operational efficiency and margin expansion. With a market cap of $12.6 billion and a forward‑looking outlook that includes a 500‑basis‑point margin lift in the second half, the company offers a stable earnings engine. Its valuation at $267.49 per share sits near the 52‑week high of $268, suggesting a modest upside potential relative to the mean analyst target of $267.71. Risks remain in regulatory approvals for new trial services and competitive pressure from larger contract research organizations, but the company’s consistent earnings beat streak mitigates short‑term volatility.
What drives CRL stock price?
Primary price drivers for CRL include the growth trajectory of its DSA segment, which has consistently outpaced revenue and EPS growth in the last two quarters. 2026 Q2 revenue of $1.004 billion and a 46% EPS increase to $3.02 underscore the segment’s contribution to top‑line expansion. Additionally, the company’s ability to maintain a 1.19× book‑to‑bill ratio signals strong demand for its safety assessment services. Market sentiment, reflected in a 70% sentiment score and stable trend, also supports the stock’s upward momentum. Finally, analyst upgrades from major banks and a consensus buy rating reinforce investor confidence.
Does Charles River Laboratories pay a dividend?
Charles River Laboratories does not currently distribute a dividend to shareholders. The company’s capital allocation strategy prioritizes reinvestment in research and development to sustain its competitive edge in the preclinical services market. This approach aligns with the broader industry trend of prioritizing growth over cash payouts. Investors seeking income would need to look elsewhere, while those focused on growth may find CRL’s reinvestment model attractive. The absence of a dividend does not diminish the company’s valuation, which is driven by earnings growth and margin expansion.
How is CRL valued compared to peers?
CRL trades at a forward‑price‑to‑earnings multiple that is lower than the peer average of 53.0, reflecting its robust earnings trajectory and margin improvement. At $267.49 per share, the stock sits near its 52‑week high, indicating a valuation premium relative to its historical range but still below the upper analyst target of $310. The company’s market cap of $12.6 billion places it in the mid‑cap tier within the diagnostics & research sector. Comparatively, peers such as Abbott Laboratories and AbbVie trade at higher multiples, suggesting CRL may be undervalued on a growth basis. Analysts view the valuation as justified by the company’s consistent earnings beat streak and expanding DSA revenue.
What are the risks of buying CRL?
Key risks include potential regulatory delays for new clinical trial services that could slow revenue growth. Earnings volatility is evident, with Q4‑2025 EPS declining to $2.39 from an estimate of $2.56, indicating sensitivity to operational fluctuations. Competitive pressure from larger contract research organizations may erode market share if CRL cannot sustain its margin expansion. Additionally, the company’s reliance on a few large clients for a significant portion of revenue exposes it to concentration risk. Finally, macroeconomic factors such as a slowdown in pharmaceutical R&D spending could impact demand for preclinical services.
How does CRL compete with other preclinical service providers?
CRL’s competitive advantage lies in its integrated service model spanning Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company’s DSA segment, with a 1.19× book‑to‑bill ratio, showcases strong demand for its safety assessment services, setting it apart from peers that focus solely on model supply. Its manufacturing solutions offer specialized testing for biologics, adding a differentiated revenue stream. The breadth of services allows CRL to capture cross‑sell opportunities within the drug development lifecycle. Moreover, strategic collaborations and alliances reinforce its market position and broaden its service portfolio.
What are the recent earnings results for CRL?
In Q2‑2026, CRL reported revenue of $1.004 billion, up 0.8% YoY, and diluted EPS of $3.02, a 46% increase from the prior quarter. Q1‑2026 revenue reached $995.8 million, a modest 0.1% rise from Q4‑2025’s $994.2 million, while EPS fell to $2.06 from $2.39, a 13% decline. The company has consistently beaten analyst EPS estimates, except for Q4‑2025 when it missed. Revenue trends show a slight YoY decline of 2.8% in Q2‑2026, but EPS volatility has been pronounced, reflecting operational efficiencies and margin expansion. Analysts note that the adjusted EPS outlook remains positive despite a trimmed 2026 GAAP EPS guidance.
How has CRL stock performed over the past year?
CRL’s stock has delivered a 64.6% return over the past year, outperforming its 52‑week high of $268 by a narrow margin. In the last 12 months, the stock rallied 53.3% over 6 months and 47.2% over 3 months, indicating a sustained acceleration in price momentum. The 1‑month return of 14.5% reflects recent positive earnings beats and analyst upgrades. Compared to the sector average, CRL’s performance has been notably stronger, driven by its earnings beat streak and margin expansion. The upward trend suggests that market participants are pricing in continued growth from the DSA segment.
What is the analyst consensus on CRL's price target?
Analysts currently set a mean price target of $267.71 for CRL, with a high of $310 and a low of $135. The consensus rating is overwhelmingly positive: 15 buy, 7 hold, and no sell recommendations. This distribution reflects confidence in the company’s earnings trajectory and margin expansion potential. The target range indicates that while some analysts view upside potential up to $310, others remain cautious of a $135 low, underscoring differing views on risk factors. The strong buy consensus aligns with recent upgrades from JP Morgan, Barclays, RBC, and Deutsche Bank.
What is Charles River Laboratories' revenue trend over the last two quarters?
Revenue in Q2‑2026 reached $1.004 billion, up 0.8% YoY, while Q1‑2026 revenue was $995.8 million, a 0.1% increase from Q4‑2025’s $994.2 million. The slight YoY decline of 2.8% in Q2‑2026 is offset by a 0.8% YoY increase in Q1‑2026, indicating a modest but stable revenue base. The DSA segment’s strong book‑to‑bill ratio supports continued revenue growth. These figures demonstrate that CRL is maintaining revenue momentum despite competitive pressures. The company’s consistent earnings beat streak further supports confidence in its revenue trajectory.
How is CRL's R&D investment translating into product differentiation?
CRL’s R&D focus centers on expanding its Discovery and Safety Assessment capabilities, which has led to a 1.19× book‑to‑bill ratio in Q2‑2026. This metric signals that new service offerings are quickly being adopted by clients, differentiating CRL from competitors that rely on traditional model supply. The company’s investment in specialized testing for biologics within its Manufacturing Solutions segment adds another layer of differentiation. By integrating early‑stage discovery services with manufacturing quality control, CRL creates a seamless pipeline for pharmaceutical clients. The result is a competitive moat that supports higher pricing power and margin expansion.
What is the outlook for CRL's Discovery and Safety Assessment segment?
The DSA segment is projected to experience a 500‑basis‑point margin lift in the second half of 2026, driven by increased demand for early‑stage discovery services. A 1.19× book‑to‑bill ratio in Q2‑2026 indicates robust utilization of the segment’s offerings. Analysts expect the segment to continue outpacing revenue growth relative to the overall company, reinforcing its role as a key growth engine. The segment’s expansion is supported by strategic collaborations and alliances that broaden its service portfolio. Continued focus on safety assessment services positions DSA to capture a growing share of the preclinical market.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).